Epigral Ltd
Epigral Ltd (EPIGRAL) last reported results for the quarter ended Jun 2026, with sales of ₹705 crore and net profit of ₹100 crore. The stock last traded at ₹1,033, a market capitalisation of ₹4,458 crore, on a P/E of 16.4. Over the past 52 weeks the stock has ranged between ₹806 and ₹1,746. Figures are as of 6 Oct 2026 and are not real time.
Epigral Ltd share price and key metrics
- Current price
- ₹1,033
- Market cap
- ₹4,458 cr
- Stock P/E
- 16.4
- Book value
- ₹515
- ROE
- 16.0%
- ROCE
- 15.5%
- Dividend yield
- 0.49%
- 52w high / low
- 1746/806
Metrics as of 6 Oct 2026. Not real time.
Track Epigral Ltd
Cruxal reads every Epigral Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Epigral Ltd growth and returns
- 10 Years
- %
- 5 Years
- 25%
- 3 Years
- 5%
- TTM
- 5%
- 10 Years
- %
- 5 Years
- 27%
- 3 Years
- -2%
- TTM
- -37%
- 10 Years
- %
- 5 Years
- 1%
- 3 Years
- 1%
- 1 Year
- -41%
- 10 Years
- %
- 5 Years
- 24%
- 3 Years
- 18%
- Last Year
- 16%
Epigral Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹705 cr, up 16.1% from ₹607 cr a year earlier. Net profit was ₹100 cr, down 37.9% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 626 | 645 | 628 | 607 | 587 | 597 | 736 | 705 |
| Expenses | 448 | 463 | 454 | 443 | 455 | 494 | 569 | 526 |
| Operating profit | 178 | 183 | 173 | 163 | 132 | 103 | 168 | 179 |
| OPM % | 28% | 28% | 28% | 27% | 22% | 17% | 23% | 25% |
| Other income | 6 | 4 | 4 | 9 | 2 | 6 | -1 | 5 |
| Interest | 27 | -0 | 12 | 23 | 22 | 11 | 16 | 7 |
| Depreciation | 32 | 33 | 34 | 42 | 42 | 43 | 42 | 43 |
| Profit before tax | 125 | 154 | 131 | 107 | 70 | 55 | 110 | 134 |
| Tax % | 35% | 33% | 34% | -50% | 26% | 28% | 26% | 25% |
| Net profit | 81 | 104 | 87 | 161 | 51 | 39 | 81 | 100 |
| EPS (₹) | 19.57 | 24.02 | 20.14 | 37.25 | 11.87 | 9.07 | 18.76 | 23.12 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Epigral Ltd annual results
| ₹ crore | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|
| Sales | 829 | 1,551 | 2,188 | 1,929 | 2,550 | 2,527 | 2,626 |
| Operating profit | 261 | 509 | 689 | 481 | 711 | 566 | 582 |
| OPM % | 32% | 33% | 31% | 25% | 28% | 22% | 22% |
| Net profit | 101 | 253 | 353 | 196 | 358 | 332 | 271 |
| EPS (₹) | 24.48 | 60.84 | 85.03 | 47.14 | 82.91 | 76.95 | 62.82 |
TTM is the trailing twelve months to the most recent quarter.
Epigral Ltd balance sheet
| ₹ crore | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Equity capital | 42 | 42 | 42 | 42 | 43 | 43 |
| Reserves | 432 | 684 | 1,028 | 1,213 | 1,861 | 2,178 |
| Borrowings | 753 | 993 | 879 | 964 | 593 | 572 |
| Other liabilities | 222 | 405 | 484 | 576 | 655 | 712 |
| Total liabilities | 1,449 | 2,124 | 2,432 | 2,794 | 3,152 | 3,505 |
| Fixed assets | 1,102 | 1,068 | 1,804 | 1,767 | 2,238 | 2,117 |
| CWIP | 126 | 589 | 158 | 483 | 64 | 451 |
| Investments | 0 | 0 | 21 | 21 | 98 | 23 |
| Other assets | 221 | 467 | 450 | 524 | 752 | 915 |
| Total assets | 1,449 | 2,124 | 2,432 | 2,794 | 3,152 | 3,505 |
As reported by the company. Total assets equal total liabilities by construction.
Epigral Ltd cash flow
| ₹ crore | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Cash from operations | 229 | 284 | 626 | 398 | 441 | 436 |
| Cash from investing | -197 | -455 | -437 | -401 | -262 | -355 |
| Cash from financing | -32 | 195 | -200 | -8 | -164 | -94 |
| Net cash flow | 1 | 24 | -11 | -11 | 15 | -14 |
| Free cash flow | 32 | -172 | 210 | -1 | 254 | 50 |
| CFO / operating profit | 99% | 68% | 106% | 93% | 78% | 90% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Epigral Ltd operating ratios
| Per year | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| ROCE % | — | 29% | 32% | 17% | 25% | 15% |
| Debtor days | 52 | 60 | 28 | 34 | 33 | 60 |
| Inventory days | 51 | 74 | 69 | 90 | 105 | 89 |
| Days payable | 69 | 42 | 36 | 63 | 50 | 66 |
| Cash conversion cycle | 34 | 92 | 61 | 61 | 88 | 83 |
| Working capital days | -92 | -26 | -41 | -54 | 26 | 16 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Epigral Ltd shareholding pattern
Promoters held 68.83% at Jun 2026, broadly unchanged since Jun 2025. FIIs 1.03% and DIIs 5.56%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 71.58% | 68.94% | 68.95% | 68.83% | 68.83% | 68.83% | 68.83% | 68.83% |
| FIIs | 2.10% | 3.01% | 3.01% | 3.06% | 2.71% | 2.36% | 1.54% | 1.03% |
| DIIs | 1.17% | 4.31% | 4.66% | 4.78% | 4.93% | 5.13% | 4.90% | 5.56% |
| Government | 0.02% | 0.02% | 0.02% | 0.02% | 0.02% | 0.02% | 0.02% | 0.02% |
| Public | 25.12% | 23.71% | 23.34% | 23.30% | 23.52% | 23.67% | 24.71% | 24.56% |
| No. of shareholders | 83,176 | 81,697 | 80,878 | 79,951 | 78,605 | 77,562 | 77,583 | 76,305 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Epigral Ltd corporate filings
- Epigral Limited submits Notice of Closure of Trading Window.Insider Trading / SASTlow impact
- Epigral Limited to participate in Anand Rathi G-200 Summit 2026 on September 21, 2026Company Updatelow impact
Cruxal's analysis: Epigral Limited has announced its participation in the Anand Rathi Annual Flagship…
Read the full analysis - Epigral Limited schedules analyst and investor plant visit for September 3, 2026Company Updatelow impact
Cruxal's analysis: Epigral Limited has announced an investor and analyst plant visit scheduled for Thursday…
Read the full analysis - Epigral Limited schedules one-on-one investor/analyst meeting for August 20, 2026Company Updatelow impact
Cruxal's analysis: Epigral Limited has formally notified the exchange regarding a scheduled one-on-one…
Read the full analysis - Epigral Limited to participate in EMKAY Confluence 2026 on August 12, 2026Company Updatelow impact
Cruxal's analysis: Epigral Limited has announced that company officials will participate in the EMKAY…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.